Browse the evidence

High-fat diets (HFD) induce obesity and metabolic dysfunction by altering gut microbiota composition and downregulating tight junction proteins (claudin-1, claudin-2, claudin-3, ZO-1, occludin), leading to increased intestinal permeability ('leaky gut') and systemic inflammation.

Diets very high in fat (over 35% of calories) can damage your gut lining by reducing the proteins that hold gut cells together, allowing toxins into your bloodstream and causing inflammation. This process contributes to obesity and metabolic issues. To protect your gut barrier, focus on balanced fat intake rather than extreme high-fat diets, and consider fats that support microbiome health.

Bariatric surgery reduces the incidence of macro- and micro-vascular complications in obese patients with type 2 diabetes, but it does not reliably reverse established end-stage complications (such as advanced nephropathy or retinopathy) and may not improve survival in patients with advanced comorbidities.

If you have obesity and diabetes with existing vascular issues (like high blood pressure or early kidney changes), surgery can significantly lower your risk of heart attacks, strokes, and blindness. However, if you already have end-stage organ damage (like dialysis-dependent kidney failure), surgery is unlikely to reverse that damage and may carry higher risks. The goal of surgery is prevention of these events, not necessarily curing established end-stage disease.

Current methods for measuring energy intake and expenditure are insufficiently accurate for widespread clinical or research use, creating a barrier to understanding and managing obesity.

Current consumer tools like pedometers and self-reported food logs are not accurate enough to precisely track energy balance. For serious management, rely on broader behavioral changes rather than obsessing over precise calorie counts, as the margin of error in current measurement methods is high.

Real-world clinical practice fails to implement existing NAFLD guidelines, resulting in widespread underdiagnosis and suboptimal awareness.

Healthcare providers should utilize clear, simplified screening algorithms to identify at-risk patients, as current real-world implementation of guidelines is suboptimal.

Breast cancer survivors have significantly reduced cardiorespiratory fitness (peak VO2) compared to healthy controls, primarily due to impaired central cardiovascular function (lower stroke volume and cardiac output) rather than peripheral muscle extraction deficits.

Breast cancer treatment can reduce your heart's ability to pump blood during exercise, leading to lower fitness levels. This is a physiological change, not just 'being out of shape.' Targeted aerobic exercise can help improve this cardiovascular function.

GLP-1 receptor agonists delay gastric emptying, increasing the risk of pulmonary aspiration during anesthesia, necessitating specific perioperative holding periods or gastric assessment before elective surgery.

If you are taking a GLP-1 weight loss drug (like Ozempic or Wegovy) and need elective surgery, tell your surgeon and anesthesiologist immediately. These drugs slow down your stomach, which can cause dangerous aspiration during anesthesia. You may need to hold your medication for 1-3 weeks before surgery, or your surgery might be postponed until your stomach is empty. Do not skip doses without consulting your care team, as this can affect your blood sugar and weight management.

Insulin resistance in the skeletal muscle vasculature impairs capillary recruitment and nitric oxide bioavailability, which directly limits insulin-stimulated glucose uptake.

If you have insulin resistance, simply exercising may not be enough if your blood vessels aren't delivering insulin to your muscle cells effectively. Focus on strategies that improve vascular health, such as weight loss and specific medications, alongside physical activity, to ensure insulin can reach the muscle to process glucose.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACEs) and all-cause mortality in patients with type 2 diabetes, independent of glycemic control, through anti-inflammatory and plaque-stabilizing mechanisms.

If you have type 2 diabetes and high cardiovascular risk, GLP-1RAs like semaglutide or liraglutide can significantly reduce your risk of heart attack, stroke, and death. This benefit comes from stabilizing plaque and reducing inflammation, not just lowering blood sugar. Discuss these options with your doctor, especially if you have existing heart disease.

Bariatric surgery (specifically Roux-en-Y gastric bypass) can establish a new, lower body weight set point by altering gastrointestinal signals to the brainstem, thereby suppressing the counterregulatory hunger and hypometabolism typically seen after diet-induced weight loss.

For morbid obesity, surgery may be necessary to reset the body's defended weight. Unlike dieting, which triggers hunger, surgery appears to suppress this hunger biologically. However, it is invasive and requires lifelong management.

Acute moderate altitude hypoxia (2320m) does not enhance the hormonal (GH, Cortisol, Testosterone) or inflammatory (IL-6, IL-10, TNF-alpha) response to a single hypertrophy-oriented resistance training session compared to normoxia.

If you are training at moderate altitude (approx 2300m), do not expect a single resistance training session to trigger a superior acute hormonal or inflammatory response compared to training at sea level. The anabolic signaling environment (GH, Testosterone) remains similar to normoxia. Focus on maintaining training volume and intensity rather than relying on altitude for acute hormonal amplification.

Capsaicin or capsiate supplementation does not significantly improve aerobic endurance performance (time-trials or time-to-exhaustion) in healthy adults.

Do not rely on capsaicin or capsiate to improve your running or cycling times. The evidence shows no benefit for aerobic endurance, regardless of whether you do a time trial or exercise until exhaustion.

Setting unrealistic initial weight loss goals (e.g., >10% or ~20% of body weight) does not negatively impact actual weight loss outcomes or treatment attrition in behavioral weight management programs.

If you have a big weight loss goal, don't stress that it's 'unrealistic' or that it will cause you to quit. The data shows that having a high goal (like 20% body weight) does not make you less likely to lose weight or drop out of a program compared to someone with a modest goal. Focus on the behavioral steps (diet/exercise) rather than worrying that your target number is too high.

A ketogenic diet (defined as <50g carbohydrate/day or blood ketones ≥0.5 mM) has largely neutral or detrimental effects on athletic performance compared to a higher-carbohydrate diet, despite significantly increasing fat oxidation rates.

If your goal is to improve athletic performance (endurance, strength, or power), a ketogenic diet is not recommended. While it increases fat burning, it does not translate to better performance and may actually hinder it, especially in elite athletes or high-intensity efforts. Stick to a higher-carbohydrate diet for optimal results.

Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, sodium, and phosphate excretion, and insulin resistance.

Obesity increases your risk of kidney stones by changing your urine chemistry, making it more acidic and increasing stone-forming minerals. Maintaining a healthy weight can help reduce this risk.

Dysbiotic gut microbiota and its derived metabolites (such as TMAO, choline, and hippurate) are shared metabolic biomarkers across cardiometabolic diseases, contributing to inflammation, atherosclerosis, and insulin resistance.

Support gut health through a diverse, fiber-rich diet to potentially lower levels of harmful metabolites like TMAO, which are linked to cardiovascular risk and insulin resistance.

Metformin treatment alters gut microbiota composition (increasing Escherichia coli and decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.

If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fatty acids. This is a key part of how the drug works, though it can cause temporary stomach upset for some people.

Obesity pharmacotherapy primarily reduces metabolizable energy intake (DEI) through a universal exponential time course characterized by a large initial decrease followed by a slow relaxation to a smaller persistent effect.

If you are taking an obesity medication, expect your appetite suppression to be strongest in the first few months. As your weight stabilizes, the drug's effect on how much you eat will settle at a lower, sustainable level rather than disappearing. This waning effect is normal and part of the drug's designed mechanism, not a sign that the treatment has failed.

A 20-minute theory-informed documentary presenting health, environmental, and animal welfare arguments does not significantly reduce actual meat and animal product (MAP) consumption over a 12-day period when social desirability bias is minimized.

Watching a documentary about the benefits of reducing meat consumption is unlikely to change your actual eating habits within two weeks, even if it makes you want to try. The study shows that while people might *say* they will eat less meat (especially if they think the researchers want them to), their actual consumption remains unchanged. To make a real change, information alone is insufficient; you need concrete plans, recipes, and environmental support, not just emotional appeals.

GLP-1 receptor agonists lower serum TSH levels in patients with Type 2 Diabetes, particularly those who experience weight loss, without necessarily changing free thyroxine (FT4) levels, suggesting a mechanism involving central nervous system GLP-1 receptors or improved thyroid hormone sensitivity.

If your TSH levels drop while on a GLP-1 medication, it is likely due to your weight loss or improved metabolic sensitivity, not necessarily a thyroid problem. Your doctor will likely check your Free T4 to ensure your thyroid function is normal. This change is generally considered a positive metabolic adaptation rather than a disease state.

The peptide drug GUB021794, a GLP-1 receptor agonist derived from a secretin backbone, promotes dose-dependent body weight loss in diet-induced obese mice comparable to the clinically approved drug semaglutide.

This research identifies a new peptide drug, GUB021794, which mimics the hormone GLP-1 to reduce appetite and body weight. In obese mice, it worked as well as the popular drug semaglutide but was designed to last longer in the body, allowing for once-weekly dosing instead of daily. This suggests a potential future treatment option for obesity that offers similar weight loss benefits with less frequent administration.

Adults with diabetes and overweight/obesity are significantly more likely to use weight-inducing (WI) medications than weight-reducing (WR) medications, with WI use being 4 to 20 times higher than WR use, despite clinical guidelines recommending preferential use of WR agents.

If you have diabetes and are overweight, your current medication might be working against your weight loss goals. Many common diabetes drugs cause weight gain. Ask your doctor about switching to weight-reducing options like GLP-1 agonists or SGLT2 inhibitors, which are now recommended for people with your profile. Be aware that these drugs can be expensive and may require injections, but they are designed to help you lose weight, unlike older medications.

Spirulina supplementation does NOT significantly preserve skeletal muscle mass (SMM) during gradual weight loss compared to placebo; both groups lost similar amounts of muscle mass.

Do not rely on spirulina to preserve your muscle mass during a weight cut. This study showed that wrestlers taking spirulina lost the same amount of muscle as those taking a placebo. To preserve muscle, you must ensure your overall protein intake is high (1.6-3.1 g/kg/day) in addition to following your gradual weight loss diet.

High body mass index (BMI) is a strong independent risk factor for the development of chronic kidney disease (CKD) and end-stage renal disease (ESRD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to prevent kidney disease. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. Focus on sustainable lifestyle changes like proper nutrition and exercise to lower your BMI, especially if you have high blood pressure or diabetes.

High BMI acts as a direct risk factor for chronic kidney disease (CKD) through compensatory renal hyperfiltration and increased intraglomerular pressure, independent of diabetes or hypertension.

Maintaining a healthy weight is critical for kidney health. High body weight forces your kidneys to work harder (hyperfiltration), which damages them over time. This damage happens even if you don't have diabetes or high blood pressure. Weight management through lifestyle changes is the primary way to prevent this specific type of kidney injury.